Evaluating new regimens in recurrent ovarian cancer: How much evidence is good enough?

Journal of Clinical Oncology

Volumn 28, Issue 19, 2010, Pages 3101-3103

  Cannistra, Stephen A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; DOXORUBICIN; EPOTHILONE DERIVATIVE; ETOPOSIDE; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PEMETREXED; TOPOTECAN; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

CANCER CHEMOTHERAPY; CONGESTIVE HEART FAILURE; EDITORIAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; TREATMENT OUTCOME; KAPLAN MEIER METHOD; NOTE; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 77955500910     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.7077     Document Type: Editorial

References (23)

1. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
2. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
3. Matulonis UA, Berlin S, Ivy P, et al: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601-5606, 2009
4. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
5. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al: Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase i, open-label, dose-escalation study. J Clin Oncol 27:3097-3103, 2009
6. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol doi:10.1200/JCO.2009.25.7519 [epub ahead of print on May 24, 2010]
8. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
9. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003
10. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707, 2006 (Pubitemid 46630933)
11. Monk BJ, Herzog TJ, Kaye SB, et al: Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114, 2010
12. Sessa C, De Braud F, Perotti A, et al: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-1874, 2005
13. Takahashi N, Li WW, Banerjee D, et al: Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251-3257, 2001 (Pubitemid 32963850)
14. Markman M, Kennedy A, Webster K, et al: Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78:369-372, 2000
15. Ferrandina G, Ludovisi M, Lorusso D, et al: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890-896, 2008 (Pubitemid 351398081)
16. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818, 2007 (Pubitemid 47123191)
17. Cannistra SA: The ethics of early stopping rules: who is protecting whom? J Clin Oncol 22:1542-1545, 2004
18. US Food and Drug Administration: Cancer Drug Approval Endpoints. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ CancerDrugs/ucm094586.htm
19. Brady MF: First-line therapy in Ovarian Cancer Surrogate endpoints for accelerated approval. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094640.pdf
20. Bast RC, Thigpen JT, Arbuck SG, et al: Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop. Gynecol Oncol 107:173-176, 2007 (Pubitemid 47575741)
21. Buyse M, Molenberghs G, Burzykowski T, et al: The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49-67, 2000
22. Buyse M, Burzykowski T, Carroll K, et al: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224, 2007 (Pubitemid 350232253)
23. Freidlin B, Korn EL, Hunsberger S, et al: Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 25:2122-2126, 2007 (Pubitemid 46972800)